Comparison of the mydriatic effects of mydrin-P and compound tropicamide in the screening of retinopathy of prematurity.

眼科学报 Pub Date : 2014-12-01
Shuke Luo, Zhonghe Wan, Xiaofang Yin, Zuke Ye, Yan Lu
{"title":"Comparison of the mydriatic effects of mydrin-P and compound tropicamide in the screening of retinopathy of prematurity.","authors":"Shuke Luo,&nbsp;Zhonghe Wan,&nbsp;Xiaofang Yin,&nbsp;Zuke Ye,&nbsp;Yan Lu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To observe and compare the effects of pupil dilation between Mydrin-P and compound tropicamide in the screening of retinopathy of prematurity.</p><p><strong>Methods: </strong>The right eyes of premature infants received My- drin-P eye drops as the treatment group, whereas the left eyes were administered with compound tropicamide as the control group. The eye drops were delivered every 5 min for three times. The pupil size was observed and recorded at 10, 15, and 20 min after administering mydriasis.</p><p><strong>Results: </strong>The mean pupil diameter did not significantly differ between the treatment and control groups at 10 (6.24 ± 0.72 mm vs. 6.24 ± 0.68 mm, t = 0.00, P = 1.00), 15 (6.83 ± 0.55 mm vs. 6.78 ± 0.54 mm, t = 1.75, P = 0.083) or 20 min (7.22 ± 0.40 mm vs. 7.15 ± 0.50 mm, t = 1.62, P = 0.109), respectively. How- ever, the mean pupil size at any two time points significantly differed in both groups (all P < 0.001).</p><p><strong>Conclusion: </strong>Both Mydrin-P and compound tropicamide exert similar clinical efficacy in the screening of retinopathy of pre- maturity. The most appropriate time for screening was at 20 min after mydriasis.</p>","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To observe and compare the effects of pupil dilation between Mydrin-P and compound tropicamide in the screening of retinopathy of prematurity.

Methods: The right eyes of premature infants received My- drin-P eye drops as the treatment group, whereas the left eyes were administered with compound tropicamide as the control group. The eye drops were delivered every 5 min for three times. The pupil size was observed and recorded at 10, 15, and 20 min after administering mydriasis.

Results: The mean pupil diameter did not significantly differ between the treatment and control groups at 10 (6.24 ± 0.72 mm vs. 6.24 ± 0.68 mm, t = 0.00, P = 1.00), 15 (6.83 ± 0.55 mm vs. 6.78 ± 0.54 mm, t = 1.75, P = 0.083) or 20 min (7.22 ± 0.40 mm vs. 7.15 ± 0.50 mm, t = 1.62, P = 0.109), respectively. How- ever, the mean pupil size at any two time points significantly differed in both groups (all P < 0.001).

Conclusion: Both Mydrin-P and compound tropicamide exert similar clinical efficacy in the screening of retinopathy of pre- maturity. The most appropriate time for screening was at 20 min after mydriasis.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
mydrin-P与复方tropicamide在早产儿视网膜病变筛查中的效果比较。
目的:观察和比较Mydrin-P与复方托品酰胺瞳孔扩张在早产儿视网膜病变筛查中的作用。方法:以早产儿右眼滴入My- drin-P滴眼液为治疗组,左眼滴入复方托品酰胺为对照组。每5分钟滴眼3次。观察瞳孔大小,并记录于10、15、20分钟后给眼。结果:治疗组和对照组的平均瞳孔直径分别在10(6.24±0.72 mm vs 6.24±0.68 mm, t = 0.00, P = 1.00)、15(6.83±0.55 mm vs 6.78±0.54 mm, t = 1.75, P = 0.083)和20 min(7.22±0.40 mm vs 7.15±0.50 mm, t = 1.62, P = 0.109)时无显著差异。然而,两组在任意两个时间点的平均瞳孔大小有显著差异(均P < 0.001)。结论:Mydrin-P与复方托品酰胺筛查早产儿视网膜病变的临床疗效相近。筛检的最佳时间为虫蛀后20 min。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
1312
期刊介绍:
期刊最新文献
Uveitis secondary to cancer therapeutics Optical coherence tomography angiography of non-exudative choroidal neovascularization. Application of visual electrophysiology for the diagnosis and treatment of cataracts. Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy. Approved pharmacotherapy for myopic choroidal neovascularization: a review of randomized controlled trials in ranibizumab and aflibercept.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1